Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 1;5(4):e228879.
doi: 10.1001/jamanetworkopen.2022.8879.

Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink

Kayla E Hanson  1 , Kristin Goddard  2 , Ned Lewis  2 , Bruce Fireman  2 , Tanya R Myers  3 , Nandini Bakshi  4 , Eric Weintraub  3 , James G Donahue  1 , Jennifer C Nelson  5 , Stan Xu  6 , Jason M Glanz  7 , Joshua T B Williams  8 , Jonathan D Alpern  9 , Nicola P Klein  2
Affiliations

Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink

Kayla E Hanson et al. JAMA Netw Open. .

Abstract

Importance: Postauthorization monitoring of vaccines in a large population may detect rare adverse events not identified in clinical trials such as Guillain-Barré syndrome (GBS), which has a background rate of 1 to 2 per 100 000 person-years.

Objective: To describe cases and incidence of GBS following COVID-19 vaccination and assess the risk of GBS after vaccination for Ad.26.COV2.S (Janssen) and mRNA vaccines.

Design, setting, and participants: This cohort study used surveillance data from the Vaccine Safety Datalink at 8 participating integrated health care systems in the United States. There were 10 158 003 participants aged at least 12 years. Data analysis was performed from November 2021 to February 2022.

Exposures: Ad.26.COV2.S, BNT162b2 (Pfizer-BioNTech), or mRNA-1273 (Moderna) COVID-19 vaccine, including mRNA vaccine doses 1 and 2, December 13, 2020, to November 13, 2021.

Main outcomes and measures: GBS with symptom onset in the 1 to 84 days after vaccination, confirmed by medical record review and adjudication. Descriptive characteristics of confirmed cases, GBS incidence rates during postvaccination risk intervals after each type of vaccine compared with the background rate, rate ratios (RRs) comparing GBS incidence in the 1 to 21 vs 22 to 42 days postvaccination, and RRs directly comparing risk of GBS after Ad.26.COV2.S vs mRNA vaccination, using Poisson regression adjusted for age, sex, race and ethnicity, site, and calendar day.

Results: From December 13, 2020, through November 13, 2021, 15 120 073 doses of COVID-19 vaccines were administered to 7 894 989 individuals (mean [SE] age, 46.5 [0.02] years; 8 138 318 doses received [53.8%] by female individuals; 3 671 199 doses received [24.3%] by Hispanic or Latino individuals, 2 215 064 doses received [14.7%] by Asian individuals, 6 266 424 doses received [41.4%] by White individuals), including 483 053 Ad.26.COV2.S doses, 8 806 595 BNT162b2 doses, and 5 830 425 mRNA-1273 doses. Eleven cases of GBS after Ad.26.COV2.S were confirmed. The unadjusted incidence rate of GBS per 100 000 person-years in the 1 to 21 days after Ad.26.COV2.S was 32.4 (95% CI, 14.8-61.5), significantly higher than the background rate, and the adjusted RR in the 1 to 21 vs 22 to 42 days following Ad.26.COV2.S was 6.03 (95% CI, 0.79-147.79). Thirty-six cases of GBS after mRNA vaccines were confirmed. The unadjusted incidence rate per 100 000 person-years in the 1 to 21 days after mRNA vaccines was 1.3 (95% CI, 0.7-2.4) and the adjusted RR in the 1 to 21 vs 22 to 42 days following mRNA vaccines was 0.56 (95% CI, 0.21-1.48). In a head-to-head comparison of Ad.26.COV2.S vs mRNA vaccines, the adjusted RR was 20.56 (95% CI, 6.94-64.66).

Conclusions and relevance: In this cohort study of COVID-19 vaccines, the incidence of GBS was elevated after receiving the Ad.26.COV2.S vaccine. Surveillance is ongoing.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Donahue reported receiving grants from Janssen Vaccines & Prevention Funding for a study unrelated to COVID-19 vaccines outside the submitted work. Dr Nelson reported receiving grants from GlaxoSmithKline (2019-2020), nonfinancial support from ACIP/CDC as a member of COVID-19 Vaccine Safety Technical Subgroup, and grants from Moderna as a member of mRNA-1273 (COVID-19 vaccine candidate) External Safety Advisory Board for Moderna's COVID-19 vaccine program outside the submitted work. Dr Klein reported receiving grants from Pfizer research support for COVID vaccine clinical trial as well as other unrelated studies, grants from Merck, grants from GlaxoSmithKline, grants from Sanofi Pasteur, and grants from Protein Science (now Sanofi Pasteur) outside the submitted work. Dr Alpern reported receiving funding from Arnold Ventures for unrelated work. No other disclosures were reported.

Figures

Figure.
Figure.. Timing of GBS Symptom Onset after COVID-19 Vaccination
A, Bars represent the number of confirmed cases of GBS after Ad.26.COV2.S vaccination (N = 11). The x-axis denotes the numbers of days between Ad.26.COV2.S vaccination and GBS symptom onset. The 84-day follow-up period has elapsed for all Ad.26.COV2.S vaccinations. A statistically significant cluster was identified from days 1 to 14 after Ad.26.COV2.S vaccination using scan statistics (P = .003). B, Bars represent the number of confirmed cases of GBS after mRNA vaccination (N = 36). The x-axis denotes the numbers of days between most recent mRNA vaccination and GBS symptom onset. The 84-day follow-up period has elapsed for all mRNA vaccinations.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dooling K, Gargano JW, Moulia D, et al. . Use of Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years: recommendations of the Advisory Committee on Immunization Practices - United States, September 2021. MMWR Morb Mortal Wkly Rep. 2021;70(38):1344-1348. doi:10.15585/mmwr.mm7038e2 - DOI - PMC - PubMed
    1. Oliver SE, Gargano JW, Marin M, et al. . The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID-19 vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1653-1656. doi:10.15585/mmwr.mm695152e1 - DOI - PubMed
    1. Oliver SE, Gargano JW, Scobie H, et al. . The Advisory Committee on Immunization Practices’ interim recommendation for use of Janssen COVID-19 vaccine - United States, February 2021. MMWR Morb Mortal Wkly Rep. 2021;70(9):329-332. doi:10.15585/mmwr.mm7009e4 - DOI - PMC - PubMed
    1. MacNeil JR, Su JR, Broder KR, et al. . Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients - United States, April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(17):651-656. doi:10.15585/mmwr.mm7017e4 - DOI - PMC - PubMed
    1. Rosenblum HG, Hadler SC, Moulia D, et al. . Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices - United States, July 2021. MMWR Morb Mortal Wkly Rep. 2021;70(32):1094-1099. doi:10.15585/mmwr.mm7032e4 - DOI - PMC - PubMed

Publication types